If a patient with recurrent endometrial cancer experiences minimal or slow disease progression on pembrolizumab or pembro/lenvatinib, would you consider continuing or would you change agents?

Great question with unfortunately no perfect answer. There are several things that need to be considered if there is slow or minimal progression.

1. Is this true progression (patient is on immunotherapy)?
2. How well is the patient tolerating the therapy (are toxicities worth the benefit in this patient)...